Michael Greenberg - Allergan Plc Independent Director
Director
Dr. Michael E. Greenberg, Ph.D. is Director of the Company. Dr. Greenberg was Harvard Universitys Nathan Marsh Pusey Professor of Neurobiology since 2008. He was a CoLeader of Harvard Medical Schools Allen Discovery Center for Human Brain Evolution since 2017 and Chair of the Department of Neurobiology since 2008. He was also Founding Director of the F.M. Kirby Neurobiology Center, Childrens Hospital Boston, where he continues to serve as director. Prior to that he was a Professor in the Department of Microbiology Molecular Genetics at Harvard Medical School since 2018.
| Age | 63 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 862 261 7000 |
| Web | http://www.allergan.com |
Michael Greenberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Greenberg against Allergan Plc stock is an integral part of due diligence when investing in Allergan Plc. Michael Greenberg insider activity provides valuable insight into whether Allergan Plc is net buyers or sellers over its current business cycle. Note, Allergan Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allergan Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Greenberg over a month ago Disposition of 152659 shares by Michael Greenberg of Skechers USA at 60.6042 subject to Rule 16b-3 |
Allergan Plc Management Efficiency
The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Mason | MI Homes | 60 | |
| Joyce Mullen | Toro Co | 58 | |
| Geoffrey Moore | nLIGHT Inc | 71 | |
| Robert Morse | Amkor Technology | 62 | |
| Elizabeth Ingram | MI Homes | 49 | |
| Bill Gossman | nLIGHT Inc | 56 | |
| Douglas Carlisle | nLIGHT Inc | 61 | |
| Michael Vale | Toro Co | 54 | |
| Ivanhoe Donaldson | Micron Technology | N/A | |
| Mark Heil | Micron Technology | 52 | |
| Raymond Link | nLIGHT Inc | 64 | |
| Jeffrey Harmening | Toro Co | 53 | |
| Barry Porter | Hudson Pacific Properties | 62 | |
| John Schreiber | Hudson Pacific Properties | 67 | |
| Michael Nash | Hudson Pacific Properties | 53 | |
| Peggy Scott | Eastern Co | 66 | |
| Mercedes Johnson | Micron Technology | 63 | |
| Richard Fried | Hudson Pacific Properties | 53 | |
| Robert Harris | Hudson Pacific Properties | 62 | |
| Greg Johnson | Amkor Technology | N/A | |
| Daniel Liao | Amkor Technology | N/A | |
Management Performance
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 |
Allergan Plc Leadership Team
Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, Chief Financial Officer, Executive Vice President | ||
| Robert Bailey, Chief Legal Officer and Corporate Secretary | ||
| Robert Stewart, Executive VP and President of Generic and Global Operations | ||
| Ronald Taylor, Independent Director | ||
| Adriane Brown, Independent Director | ||
| William Meury, Executive Vice President, Chief Commercial Officer | ||
| Brenton Saunders, Chairman of the Board, President, Chief Executive Officer | ||
| Wayne Swanton, Executive Vice President - Global Operations | ||
| Robert Hugin, Independent Director | ||
| Nicholson, Chief R&D Officer | ||
| Christopher Bodine, Independent Director | ||
| Karen Ling, Chief Human Resource Officer, Executive Vice President | ||
| Michael Gallagher, Lead Independent Director | ||
| Paul Bisaro, Executive Chairman | ||
| Thomas Freyman, Independent Director | ||
| Catherine Klema, Lead Independent Director | ||
| James DArecca, Chief Accounting Officer | ||
| Christopher Coughlin, Lead Independent Director | ||
| Nesli Basgoz, Independent Director | ||
| Philippe Schaison, Executive Vice President and President Allergan Medical | ||
| Maria Hilado, CFO and Executive VP | ||
| Joseph Boccuzi, Independent Director | ||
| Patrick OSullivan, Independent Director | ||
| Fred Weiss, Independent Director | ||
| A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary | ||
| Alex Kelly, Chief Communications Officer | ||
| CDavid Nicholson, Executive Vice President, Chief R&D Officer | ||
| Carol Davidson, Independent Director | ||
| Michael Greenberg, Independent Director | ||
| Ron Taylor, Independent Director | ||
| Jonathon Kellerman, Executive Vice President Chief Compliance Officer | ||
| Paul Navarre, Executive Vice President and President International Brands | ||
| James Bloem, Independent Director | ||
| Karina Calzadilla, IR Contact Officer | ||
| Peter McDonnell, Independent Director |
Allergan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0913 | |||
| Return On Asset | -0.0564 | |||
| Profit Margin | (0) % | |||
| Operating Margin | 6.84 % | |||
| Current Valuation | 81.41 B | |||
| Shares Outstanding | 328.1 M | |||
| Shares Owned By Insiders | 0.16 % | |||
| Shares Owned By Institutions | 98.25 % | |||
| Number Of Shares Shorted | 15.01 M | |||
| Price To Earning | 24.00 X |
Pair Trading with Allergan Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Parker Hannifin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Parker Hannifin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Parker Hannifin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Parker Hannifin to buy it.
The correlation of Parker Hannifin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Parker Hannifin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Parker Hannifin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Parker Hannifin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Allergan Stock
If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |